Just six weeks after receiving an application, the FDA has handed out an accelerated approval to Boehringer Ingelheim’s Hernexeos, allowing its use in patients with unresectable or metastatic non-small cell lung cancer carrying certain mutations.

The approval, granted Thursday, is the second to come under the regulator’s new Commissioner’s National Priority Voucher (CNPV) program. The first was given to generics maker USAntibiotics in December 2025 for the antibiotic Augmentin XR. CNPV tickets are awarded to companies that align with certain national priorities set by the government. When used, the vouchers can shave review times from 10-12 months to 1-2 months.